Cargando…
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
Background. We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods. In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and hig...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766741/ https://www.ncbi.nlm.nih.gov/pubmed/33339402 http://dx.doi.org/10.3390/jcm9124066 |
_version_ | 1783628791358160896 |
---|---|
author | Capasso, Nicola Palladino, Raffaele Montella, Emma Pennino, Francesca Lanzillo, Roberta Carotenuto, Antonio Petracca, Maria Iodice, Rosa Iovino, Aniello Aruta, Francesco Pastore, Viviana Buonomo, Antonio Riccardo Zappulo, Emanuela Gentile, Ivan Triassi, Maria Brescia Morra, Vincenzo Moccia, Marcello |
author_facet | Capasso, Nicola Palladino, Raffaele Montella, Emma Pennino, Francesca Lanzillo, Roberta Carotenuto, Antonio Petracca, Maria Iodice, Rosa Iovino, Aniello Aruta, Francesco Pastore, Viviana Buonomo, Antonio Riccardo Zappulo, Emanuela Gentile, Ivan Triassi, Maria Brescia Morra, Vincenzo Moccia, Marcello |
author_sort | Capasso, Nicola |
collection | PubMed |
description | Background. We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods. In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher’s exact test, chi square test, or McNemar’s test, as appropriate, to evaluate between-group differences. Results. We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) (p < 0.001), and similar to the low-risk population (n = 11, 1.3%) (p = 0.057); these results were also confirmed after random matching by age and sex (1:1:1). No significant differences were found in demographic, clinical, treatment, and laboratory features. Among MS patients positive to SARS-CoV-2 IgG/IgM (n = 9), only two patients retrospectively reported mild and short-lasting COVID-19 symptoms. Conclusions. MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression. |
format | Online Article Text |
id | pubmed-7766741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77667412020-12-28 Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg Capasso, Nicola Palladino, Raffaele Montella, Emma Pennino, Francesca Lanzillo, Roberta Carotenuto, Antonio Petracca, Maria Iodice, Rosa Iovino, Aniello Aruta, Francesco Pastore, Viviana Buonomo, Antonio Riccardo Zappulo, Emanuela Gentile, Ivan Triassi, Maria Brescia Morra, Vincenzo Moccia, Marcello J Clin Med Article Background. We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. Methods. In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher’s exact test, chi square test, or McNemar’s test, as appropriate, to evaluate between-group differences. Results. We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) (p < 0.001), and similar to the low-risk population (n = 11, 1.3%) (p = 0.057); these results were also confirmed after random matching by age and sex (1:1:1). No significant differences were found in demographic, clinical, treatment, and laboratory features. Among MS patients positive to SARS-CoV-2 IgG/IgM (n = 9), only two patients retrospectively reported mild and short-lasting COVID-19 symptoms. Conclusions. MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression. MDPI 2020-12-16 /pmc/articles/PMC7766741/ /pubmed/33339402 http://dx.doi.org/10.3390/jcm9124066 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Capasso, Nicola Palladino, Raffaele Montella, Emma Pennino, Francesca Lanzillo, Roberta Carotenuto, Antonio Petracca, Maria Iodice, Rosa Iovino, Aniello Aruta, Francesco Pastore, Viviana Buonomo, Antonio Riccardo Zappulo, Emanuela Gentile, Ivan Triassi, Maria Brescia Morra, Vincenzo Moccia, Marcello Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg |
title | Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg |
title_full | Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg |
title_fullStr | Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg |
title_full_unstemmed | Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg |
title_short | Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg |
title_sort | prevalence of sars-cov-2 antibodies in multiple sclerosis: the hidden part of the iceberg |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766741/ https://www.ncbi.nlm.nih.gov/pubmed/33339402 http://dx.doi.org/10.3390/jcm9124066 |
work_keys_str_mv | AT capassonicola prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT palladinoraffaele prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT montellaemma prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT penninofrancesca prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT lanzilloroberta prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT carotenutoantonio prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT petraccamaria prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT iodicerosa prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT iovinoaniello prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT arutafrancesco prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT pastoreviviana prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT buonomoantonioriccardo prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT zappuloemanuela prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT gentileivan prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT triassimaria prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT bresciamorravincenzo prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg AT mocciamarcello prevalenceofsarscov2antibodiesinmultiplesclerosisthehiddenpartoftheiceberg |